“When we think about who should receive neoadjuvant therapy and has locally confined pancreatic cancer, we need to look at the resectable, borderline, and locally advanced and resectable categories,” explained Simeone, director of the Pancreatic Cancer Center at NYU Langone Health’s Perlmutter Cancer Center. Read more . . .
In early and locally advanced pancreatic cancer, treatment strategies vary depending on a patient’s resectable status, and even then, it can be challenging to determine whether neoadjuvant or adjuvant therapy should be given, said Diane Simeone, MD.